Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | KIF11 | P52732 | 2/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | LATS1 | O95835 | 1/20 | 0.38 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5999463 | 0.81 | USP2 (0.39) | USP2RAB9AKIF11CYP17A1GCGR | |
| SCHEMBL6000288 | 0.81 | TSHR (0.46) | USP2RAB9AKIF11CYP19A1KDM4E | |
| SCHEMBL29582809 | 0.80 | CYP19A1 (0.56) | USP2RAB9ACYP17A1CYP19A1 | |
| SCHEMBL29549074 | 0.80 | CYP19A1 (0.56) | USP2RAB9ACYP17A1CYP19A1 | |
| SCHEMBL5999951 | 0.80 | USP2 (0.55) | USP2RAB9AKIF11CYP17A1GCGR | |
| SCHEMBL5998796 | 0.80 | KCNN4 (0.42) | USP2RAB9AKIF11CYP17A1CYP19A1 | |
| SCHEMBL11684104 | 0.79 | USP2 (0.70) | USP2RAB9AKIF11CYP17A1GCGR | |
| SCHEMBL6000109 | 0.79 | KIF11 (0.42) | USP2RAB9AKIF11CYP19A1KDM4E | |
| SCHEMBL6000332 | 0.78 | KIF11 (0.47) | KIF11KCNN4 | |
| SCHEMBL14814698 | 0.77 | GPR55 (0.41) | USP2RAB9AKIF11CYP17A1GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | K AND K BIOSCIENCE, INC. (US) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | SIGMAR1, GRM1, GRIN2C | USP2 3011/4885RAB9A 3582/4885KIF11 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.